8. Davidson, J. y Connor, K. “Bupropion sustained release: a therapeutic overview”. J.Clin.Psychiatry, 59.Vol. 4:25-31. 1998.9. Debonnel, G. “Potential implications of sigma ligands and of neurosteroids in depression”. 152 ºEncuentro Anual de la American Psychiatric Association. 1999.10. DeVane, L. “Differential pharmacology of newer antidepressants”. J.Clin.Psychiatry, 59. Vol. 20: 85-93.1998.11. Feighner, J. “Mechanism of action of antidepressant medications”.J.Clin. Psychiatry, 60, Vol. 4: 4-11.1999.12. Frazer, A. “Norepinephrine involvement in antidepressant action”.152 º Encuentro Anual de la AmericanPsychiatric Association. 1999.13. Gelenberg, A. y Bassuk, E. The practitioner’s guide to psychoactive drugs (fourth edition); PleniumMedical Book Company, New York. Editado por Gelenberg, A. y Bassuk, E. 1997.14. Guelfi, J.; Ansseau, M. y col. “A double blind comparison of the efficacy and safety of Milnacipran andFluoxetine in depressed patients”.Int.Clin.Psychopharmacol., May; 13(3): 121-8. 1998.15. Koek, W.; Patoiseau, J. y col. “F11440, a potent, selective, high efficacy 5-HT1A receptor agonist withmarked anxiolytic and antidepressant potential”. J.Pharmacol.Exp.Ther., Oct; 287(1): 266-83. 1998.16. Kramer, M.; Cutler, N. y col. “Distinct mechanism for antidepressant activity by blockade of centralsubstance P receptors”. Science, Sept. 11; 281(5383): 1640-5. 1998.17. Larsson, H. “Metabolism of Femoxetine”. Acta Pharmacol.Toxicol, May; 48(5):424-32. 1981.18. Massana, J.; Moller, H. y col. “Reboxetine:a double blind comparison with Fluoxetine in majordepressive disorder”. Int.Clin.Psychopharmacol., Mar; 14(2): 73-80. 1999.19. Mc.Namara, M.; Kelly, J.; Harkin, A. y col. “Activity and onset of action of Reboxetine alone and incombination with Sertraline in animal model of depression”. XXI Congreso del Collegium InternationaleNeuro-Psychopharmacologicum. 1998.20. Montgomery, S. “Chairman’s overview.The place of Reboxetine in antidepressant therapy”.J.Clin.Psychiatry, 59, Vol. 14: 26-9. 1998.21. Montgomery, S.; Prost, J. y Briley, M. “Efficacy and tolerability of Milnacipran: an overview”.Int.Clin.Psychopharmacol. Sep 11, Vol. 4:47-51. 1998.22. Mucci, M. “Reboxetine: a review of antidepressant tolerability”. J.of Psychopharmacol., Vol. 11:S33-S37. 1997.23. Pande, A. “Igmesine, a novel sigma ligand, has antidepressant properties”. XXI Congreso delCollegium Internationale Neuro-Psychopharmacologicum. 1998.24. Rovei, V.; Mitchard, M. y col. “Pharmacokinetics and relative bioavailability studies of Cimoxatone inhumans”. Int.J.Clin.Pharmacol.Ther.Toxicol, Ene; 22(1):56-62. 1984.25. Shatzberg, A. “Clinical efficacy of Reboxetine in major depression”. 152º Encuentro Anual de laAmerican Psychiatric Association.1999.26. Shatzberg, A.; Cole, J. y De Battista, C. Manual of clinical psychopharmacology (third edition).American Psychiatric Press, Washington, D.C. Ed. por Shatzberg, Cole y De Battista. 1997.27. Shatzberg, A. y Nemeroff, Ch. Textbook of psychopharmacology (second edtion). The AmericanPsychiatric Press, Washington D.C. Ed. por Shatzberg y Nemeroff. 1998.28. Spencer, C. “Milnacipran. A review of its use in depression”. Drugs, Sept. 56(3): 405-27. 1998.29. Stahl, S.; Samburanis, A. y col. “Development of new antidepressants”. J.Clin.Psychiatry; 58, Vol. 6:40-53.30. Steen, A. y Den Boer, J. “A double blind six month comparative study of Milnacipran and Clomipraminein major depressive disorder”. Int.Clin.Psychopharmacol., Sept. 12(5):269-81. 1997.31. Suominen, J y Elosuo, R. “Efficacy and tolerance of Femoxetine and Imipramine in the treatment ofdepressive states. A randomized, double blind study. Pharmacopsychiatry, Sept. 2(5): 238-44. 1998.32. Szabadi, E.; Bradshaw, C. y col. ”The human pharmacology of Reboxetine”. Hum.Psychopharmacol.,Vol. 13, S3-S12. 1998.8
Loading...
Loading...